<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05068492</url>
  </required_header>
  <id_info>
    <org_study_id>CHESS2104</org_study_id>
    <nct_id>NCT05068492</nct_id>
  </id_info>
  <brief_title>A Novel Imging Based Quantitative Model-aided Detection of Portal Hypertension in Patients With Cirrhosis</brief_title>
  <official_title>A Novel Imging Based Quantitative Model-aided Detection of Portal Hypertension in Patients With Cirrhosis (CHESS2104): A Nationwide Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepatopancreatobiliary Surgery Institute of Gansu Province</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Portal hypertension Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Interventional Medicine Branch of Chinese Hospital Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hepatopancreatobiliary Surgery Institute of Gansu Province</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Noninvasive and accurate methods are needed to identify patients with clinically significant&#xD;
      portal hypertension (CSPH). We plan to investigate the ability of AI analysis of computed&#xD;
      tomography (CT) or magnetic resonance (MR) to identify patients with CSPH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 23, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic value</measure>
    <time_frame>12 months</time_frame>
    <description>With HVPG as the gold standard, a non-invasive HVPG model was established and validated based on enhanced computed tomography (CT) or enhanced magnetic resonance imaging (MRI) combined with artificial intelligence to evaluate portal vein hypertension</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Training cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Test cohort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CT</intervention_name>
    <description>enhanced CT with standard procedure</description>
    <arm_group_label>Test cohort</arm_group_label>
    <arm_group_label>Training cohort</arm_group_label>
    <arm_group_label>Validation cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>enhanced MRI with standard procedure</description>
    <arm_group_label>Test cohort</arm_group_label>
    <arm_group_label>Training cohort</arm_group_label>
    <arm_group_label>Validation cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HVPG</intervention_name>
    <description>HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures</description>
    <arm_group_label>Test cohort</arm_group_label>
    <arm_group_label>Training cohort</arm_group_label>
    <arm_group_label>Validation cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Organize paticipating units to collect standard-of-care data including radiological and&#xD;
        clinical data. Patients diagnosed with cirrhosis who received HVPG measurement and enhanced&#xD;
        abdominal CT/MRI scan should be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed cirrhosis (laboratory, imaging and clinical symptoms); with enhanced&#xD;
             abdominal CT scan within 14 days prior to HVPG measurement; age &gt; 18 years old;&#xD;
             written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any previous liver or spleen surgery; liver cancer; chronic acute liver failure; acute&#xD;
             portal hypertension; unreliable HVPG or CT results due to technical reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaolong Qi, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yifei Huang</last_name>
    <email>huangyf1995@foxmail.com</email>
  </overall_contact>
  <reference>
    <citation>Liu Y, Ning Z, Örmeci N, An W, Yu Q, Han K, Huang Y, Liu D, Liu F, Li Z, Ding H, Luo H, Zuo C, Liu C, Wang J, Zhang C, Ji J, Wang W, Wang Z, Wang W, Yuan M, Li L, Zhao Z, Wang G, Li M, Liu Q, Lei J, Liu C, Tang T, Akçalar S, Çelebioğlu E, Üstüner E, Bilgiç S, Ellik Z, Asiller ÖÖ, Liu Z, Teng G, Chen Y, Hou J, Li X, He X, Dong J, Tian J, Liang P, Ju S, Zhang Y, Qi X. Deep Convolutional Neural Network-Aided Detection of Portal Hypertension in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2020 Dec;18(13):2998-3007.e5. doi: 10.1016/j.cgh.2020.03.034. Epub 2020 Mar 21.</citation>
    <PMID>32205218</PMID>
  </reference>
  <reference>
    <citation>Liu F, Ning Z, Liu Y, Liu D, Tian J, Luo H, An W, Huang Y, Zou J, Liu C, Liu C, Wang L, Liu Z, Qi R, Zuo C, Zhang Q, Wang J, Zhao D, Duan Y, Peng B, Qi X, Zhang Y, Yang Y, Hou J, Dong J, Li Z, Ding H, Zhang Y, Qi X. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. EBioMedicine. 2018 Oct;36:151-158. doi: 10.1016/j.ebiom.2018.09.023. Epub 2018 Sep 27.</citation>
    <PMID>30268833</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</investigator_affiliation>
    <investigator_full_name>Xiaolong Qi</investigator_full_name>
    <investigator_title>Chief, Institute of Portal Hypertension, The First Hospital of Lanzhou University</investigator_title>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>portal hypertension</keyword>
  <keyword>AI</keyword>
  <keyword>CT</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

